Related Experiment Videos
[Malignant hyperthermia - therapy results with dantrolene. A case report]
Anasthesie, Intensivtherapie, Notfallmedizin
|October 1, 1983
Summary
Malignant hyperthermia, a rare anesthesia complication, was successfully treated in a child using dantrolene. This case highlights the critical role of prompt diagnosis and intervention with dantrolene in managing this life-threatening condition.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- General anesthesia, particularly with volatile agents like halothane and muscle relaxants such as succinylcholine, carries a risk of triggering malignant hyperthermia.
- Malignant hyperthermia is a hypermetabolic crisis characterized by rapid temperature increase, muscle rigidity, and autonomic dysfunction.
Observation:
- A 5-year-old girl developed classic symptoms of malignant hyperthermia, including rigor, tachycardia, cardiac dysrhythmia, and a rapid temperature rise to 42.6°C during appendectomy under halothane anesthesia.
- Initial cooling measures were insufficient, necessitating prompt pharmacological intervention.
Findings:
- Intravenous administration of dantrolene, initiated rapidly and followed by a calculated dosage, effectively reversed the hypermetabolic crisis.
- The patient's temperature normalized to 37.5°C within an hour of dantrolene administration, and the postoperative course was uncomplicated.
Implications:
- This case underscores the efficacy of dantrolene as a primary treatment for malignant hyperthermia in pediatric patients.
- Early recognition of malignant hyperthermia symptoms and immediate dantrolene administration are crucial for preventing severe morbidity and mortality.
- Further review of literature supports dantrolene's established value in managing human malignant hyperthermia cases.